This content is machine translated Migraine prophylaxis with CGRP-mAb New sub-analysis on fremanezumab shows risks of treatment breaks At this year’s congress of the European Association of Neurology (EAN) in Helsinki, a sub-analysis of the PEARL data was presented, which shows possible negative effects of treatment breaks on…
View Post 3 min This content is machine translated Migraine prophylaxis Positive long-term data on fremanezumab The CGRP inhibitor proved to be an effective and safe medication in patients with chronic and episodic migraine when used over a 12-month period. Data from the extension study were…
